Scientists at the Wellcome Sanger Institute have discovered that CRISPR/Cas9 gene editing can cause greater genetic damage in cells than was previously thought. These results create safety implications for gene therapies using CRISPR/Cas9 in the future as the unexpected damage could lead to dangerous changes in some cells.
Reported today (16 July 2018) in the journal Nature Biotechnology, the study also revealed that standard tests for detecting DNA changes miss finding this genetic damage, and that caution and specific testing will be required for any potential gene therapies.
CRISPR/Cas9 is one of the newest genome editing tools. It can alter sections of DNA in cells by cutting at specific points and introducing changes at that location. Already extensively used in scientific research, CRISPR/Cas9 has also been seen as a promising way to create potential genome editing treatments for diseases such as HIV, cancer or sickle cell disease. Such therapeutics could inactivate a disease-causing gene, or correct a genetic mutation. However, any potential treatments would have to prove that they were safe.
Previous research had not shown many unforeseen mutations from CRISPR/Cas9 in the DNA at the genome editing target site. To investigate this further the researchers carried out a full systematic study in both mouse and human cells and discovered that CRISPR/Cas9 frequently caused extensive mutations, but at a greater distance from the target site.
The researchers found many of the cells had large genetic rearrangements such as DNA deletions and insertions. These could lead to important genes being switched on or off, which could have major implications for CRISPR/Cas9 use in therapies. In addition, some of these changes were too far away from the target site to be seen with standard genotyping methods.
“This is the first systematic assessment of unexpected events resulting from CRISPR/Cas9 editing in therapeutically relevant cells, and we found that changes in the DNA have been seriously underestimated before now. It is important that anyone thinking of using this technology for gene therapy proceeds with caution, and looks very carefully to check for possible harmful effects.”
Professor Allan Bradley, corresponding author on the study from the Wellcome Sanger Institute
“My initial experiment used CRISPR/Cas9 as a tool to study gene activity, however it became clear that something unexpected was happening. Once we realised the extent of the genetic rearrangements we studied it systematically, looking at different genes and different therapeutically relevant cell lines, and showed that the CRISPR/Cas9 effects held true.”
Michael Kosicki, the first author from the Wellcome Sanger Institute
The work has implications for how CRISPR/Cas9 is used therapeutically and is likely to re-spark researchers’ interest in finding alternatives to the standard CRISPR/Cas9 method for gene editing.
“This study is the first to assess the repertoire of genomic damage arising at a CRISPR/Cas9 cleavage site. While it is not known if genomic sites in other cell lines will be affected in the same way, this study shows that further research and specific testing is needed before CRISPR/Cas9 is used clinically.”
Professor Maria Jasin, an independent researcher from Memorial Slone Kettering Cancer Centre, New York, who was not involved in the study
The Latest on: CRISPR/Cas9
via Google News
The Latest on: CRISPR/Cas9
- CRISPR Drapes Invisibility Cloak over Stem Cells on February 19, 2019 at 6:41 am
An international research team has used CRISPR-Cas9 gene editing to render induced pluripotent stem cells (iPSCs) invisible to the immune system, a bioengineering sleight of hand that initial in vivo ... […]
- CRISPR Gene Editing Makes Stem Cells ‘Invisible’ to Immune System on February 19, 2019 at 6:06 am
UC San Francisco scientists have used the CRISPR-Cas9 gene-editing system to create the first pluripotent stem cells that are functionally “invisible” to the immune system, a feat of biological engine... […]
- CRISPR technology creates pluripotent stem cells that are 'invisible' to the immune system on February 18, 2019 at 10:17 am
UC San Francisco scientists have used the CRISPR-Cas9 gene-editing system to create the first pluripotent stem cells that are functionally "invisible" to the immune system, a feat of biological engine... […]
- Development of a CRISPR/Cas9-based therapy for Hutchinson–Gilford progeria syndrome on February 18, 2019 at 8:38 am
CRISPR/Cas9-based therapies hold considerable promise for the treatment of genetic diseases. Among these, Hutchinson–Gilford progeria syndrome, caused by a point mutation in the LMNA gene, stands out ... […]
- Single-dose CRISPR–Cas9 therapy extends lifespan of mice with Hutchinson–Gilford progeria syndrome on February 18, 2019 at 8:32 am
Hutchinson–Gilford progeria syndrome (HGPS) is a rare lethal genetic disorder characterized by symptoms reminiscent of accelerated aging. The major underlying genetic cause is a substitution mutation ... […]
- Global Gene Therapy Research Report 2019: Technologies, Markets & Companies, 2017-2027 with Analysis of CRISPR-Cas9 and CAR-T Cell Therapies on February 18, 2019 at 3:15 am
DUBLIN, Feb. 18, 2019 /PRNewswire/ -- The "Gene Therapy - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. Gene therapy can be bro... […]
- Can Researchers Use Gene-Editing to Make Gluten-Safe Wheat? on February 14, 2019 at 3:39 pm
Celiac.com 02/11/2019 - Researchers have shown that CRISPR-Cas9 gene-editing technology can be used to remove epitopes from gliadin protein in gluten. These molecules trigger the adverse immune respon... […]
- Simultaneous Invention as Secondary Evidence of Obviousness on February 14, 2019 at 5:37 am
The outcome of the interference rested on whether the claims of 12 patents and one application owned by Broad, all directed to CRISPR-Cas9 system, were obvious over those of UC’s Application No. 13/84... […]
- BTIG likes CRISPR/Cas9 gene editors in premarket analyst action on February 8, 2019 at 4:43 am
CRISPR Therapeutics (NASDAQ:CRSP) initiated with Buy rating and $43 (43% upside) price target at BTIG Research. Editas Medicine (NASDAQ:EDIT) initiated with Buy rating and $30 (54% upside) price ... […]
via Bing News